Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2917-2931

  Kissau, Lars ^a,b   Stahl, Petra ^a,b,d   Mazitschek, Ralph ^c   Giannis, Athannasios ^c   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NAKIJIQUINONE C; NAKIJIQUINONE D; NATURAL PRODUCT; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PROTEIN DOMAIN; PROTEIN FOLDING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; BENZOQUINONES; COMBINATORIAL CHEMISTRY TECHNIQUES; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RECEPTOR, TIE-2; SERINE; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0038798615     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0307943     Document Type: Article

References (52)

1. Hubbard, S. R.; Till, J. H. Protein Tyrosine Kinases: Structure and Function. Annu. Rev. Biochem. 2000, 69, 373-98.
2. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248.
3. Hiratsuka, S.; Maru, Y.; Okada, A.; Seiki, M.; Noda, T.; Shibuya, M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001, 61, 1207-1213.
4. Kubo, H.; Fujiwara, T.; Jussila, L.; Hashi, H.; Ogawa, M.; Shimizu, K.; Awane, M.; Sakai, Y.; Takabayashi, A.; Alitalo, K.; Yamaoka, Y.; Nishikawa, S. I. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000, 96, 546-553.
5. Stratmann, A.; Acker, T.; Burger, A. M.; Amann, K.; Risau, W.; Plate, K. H. Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int. J. Cancer 2001, 91, 273-282.
6. Stacker, S. A.; Caesar, C.; Baldwin, M. E.; Thornton, G. E.; Williams, R. A.; Prevo, R.; Jackson, D. G.; Nishikawa, S.; Kubo, H.; Achen, M. G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7, 186-191.
7. Skobe, M.; Hawighorst, T.; Jackson, D. G.; Prevo, R.; Janes, L.; Velasco, P.; Riccardi, L.; Alitalo, K.; Claffey, K.; Detmar, M.; Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7, 192-198.
8. Giannis, A.; Rübsam, F. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy. Angew. Chem. 1997, 109, 606-609; Angew. Chem., Int. Ed. Engl. 1997, 36, 588-590 and refs therein.
9. Giannis, A.; Rübsam, F. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy. Angew. Chem. 1997, 109, 606-609; Angew. Chem., Int. Ed. Engl. 1997, 36, 588-590 and refs therein.
10. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257 and refs therein.
11. O'Connor, R.; Fennely, C.; Krause, D. Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem. Soc. Trans. 2000, 28, 47-51.
12. Hudziak, R. M.; Ullrich, A. Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum. J. Biol. Chem. 1991, 266, 24109-14115.
13. Heldin, C.-H.; Rönnstrand, L. Growth factor receptor in cell transformation. In Oncogenes and Tumor Suppressors; Peters, G., Vousden, K., Eds.; Oxford University Press, Cary, NC, 1997; pp 55-85.
14. Cohen, P. Protein kinases- the major drug targets of the twenty-first century? Nat. Rev. Cancer 2002, 1, 309-315.
15. Bridges, A. J. Chemical Inhibitors of Protein Kinases. Chem. Rev. 2001, 101, 2541-2571.
16. Breinbauer, R.; Vetter, I.; Waldmann, H. From Protein Domains to Drug Candidates - Natural Products as Guiding Principles in the Design and Synthesis of Compound Libraries. Angew. Chem., Int. Ed. 2002, 41, 2878-2890.
17. Part of this work was published in preliminary form: Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. Natural Product Derived Receptor Tyrosine Kinase Inhibitors: Identification of IGF1R, Tie-2 and VEGFR-3 Inhibitors. Angew. Chem., Int. Ed. 2002, 41,1174-1178.
18. Kobayashi, J.; Madono, T.; Shigemori, H. Nakijiquinones C and D, New Sesquiterpenoid Quinones with a Hydroxy Amino Acid Residue from a Marine Sponge Inhibiting c-erbB-2 Kinase. Tetrahedron 1995, 51, 10867-10874.
19. Stahl, P.; Kissau, L.; Mazitschek, R.; Huwe, A.; Furet, P.; Giannis, A.; Waldmann, H. Total Synthesis and Biological Evaluation of the Nakijiquinones. J. Am. Chem. Soc. 2001, 123, 11586-11593.
20. See e. g. Bold, G.; Altmann, K.-H.; Frei, J.; Marc, L.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis. J. Med. Chem. 2000, 43, 2310-2323 and refs therein.
21. Ishizaki, M.; Ozaki, K.; Kanematsu, A.; Isoda, T. Hoshino, Synthetic approaches toward spiro[2,3-dihydro-4H-1-benzopyran-4,1′-cyclohexan]-2-one derivatives via radical reactions: total synthesis of (±)-lycoramine. O. J. Org. Chem. 1993, 58, 3877-3885.
22. Wakamatsu, T.; Nishi, T.; Ohnuma, T.; Ban, Y. A convenient synthesis of juglone via neutral salcomine oxidation. Synth. Commun. 1984, 14, 1167-1173.
23. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483.
24. Dolan, S. C.; Millan, J. M. A New Method for the Deoxygenation of Tertiary and Secondary Alcohols. J. Chem. Soc., Chem. Commun. 1985, 22, 1588-1589.
25. Genot, A.; Florent, J.-C.; Monneret, C. Anthracyclinone. 3. Chiral pool synthesis of anthracyclinones via tetralin intermediates. J. Org. Chem. 1987, 52, 1057-1063.
26. Takai, K.; Nitta, K.; Utimoto, K. Simple and selective method for aldehydes (RCHO) fwdarw. (E)-haloalkenes (RCH: CHX) conversion by means of a haloform-chromous chloride system. J. Am. Chem. Soc. 1986, 108, 7408-7410.
27. Harada, T.; Katsuhira, T.; Hattori, K.; Oku, A. Stereochemistry in carbenoid formation by bromine/lithium and bromine/zinc exchange reactions of gem-dibromo compounds. Tetrahedron 1994, 50, 7987-8002.
28. Kaufman, T. S. Synthesis and mass spectral data of four potential biomarkers related to the C19 tricyclanes found Australian oils and puget sound sediments. Synth. Commun. 1995, 25, 1205-1221.
29. See ref 1 and refs cited therein.
30. Olson, G. L.; Cheung, H.-C.; Morgan, K.; Saucy, G. A new synthesis of alpha.-tocopherol. J. Org. Chem. 1980, 45, 803-805.
31. A homology model of the ATP binding site of KDR has been used to evaluate the anilinophthalazine-class of RTK Inhibitors. See ref 18.
32. PDB entries 1FGI and 2FGI
33. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative Protein Structure Modeling of Genes and Genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
34. This assumption would have also permitted the choice of the IGF1R or IRK structure as a templates. Indeed, this possibility was exploited, and the resulting 3D models were also used in the evaluation of the nakijiquinone analogues. However, the sequence homology to the VEGFs and Tie-2 is lower.
35. Davis, A. M.; Teague, S. J. Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. Angew. Chem., Int. Ed. 1999, 38, 736-749.
36. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structure of the Tyrosine Kinase Domain of Fibroblast Growth Receptor in Complex with Inhibitors. Science 1997, 276, 955-960.
37. Morgenstern, B. Improvement of the segment-to-segment approach to multiple sequence alignment. Bioinformatics 1999, 15, 211-218.
38. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of Comparative Protein Modeling by MODELLER. Proteins 1995, 23, 318-326.
39. Modeller 4.0 Manual. For additional references and information please refer to Sali@rockvax.rockefeller.edu.
40. Hooft, R. W. W.; Vriend, G.; Sander, C.; Abola, E. E. Errors in protein structure. Nature 1996, 381, 272.
41. WitnotP is a molecular modeling software developed by and licensed from Novartis AG, Basel, Switzerland. For further information and licensing conditions please contact Dr. Armin Widmer at Novartis AG.
42. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem 1983, 4, 187-217.
43. For a detailed description of how this figure was created, see Experimental Section.
44. Knighton, D. R.; Zheng, J. H.; Ten Eyck, L. F.; Ashford, V. A.; Xuong, N. H.; Taylor; S. S.; Sowadski, J. M. Crystal Structure of the Catalytic Subunit of Cyclic Adenosine Monophosphate-Dependent Protein Kinase. Science 1991, 253, 407-414.
45. Arnold, L. D.; Calderwood, D. J.; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; Rafferty, P.; Ratnofsky, S. E. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck I. Bioorg. Med. Chem. Lett. 2000, 10, 2167-2170.
46. Burchat, A. F.; Calderwood, D. J.; Hirst, G. C.; Holman, N. J.; Johnston, D. N.; Munschauer, R.; Rafferty, P.; Tometzki, G. B. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck. Bioorg. Med. Chem. Lett. 2000, 10, 2171-2174.
47. Calderwood, D. J.; Johnston, D. N.; Munschauer, R.; Rafferty, P. Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lck. Bioorg. Med. Chem. Lett. 2002, 12, 1683-1686.
48. Burchat, A. F.; Calderwood, D. J.; Friedman, M. M.; Hirst, G. C.; Li, B.; Rafferty, P.; Ritter, K.; Skinner, B. S. Pyrazolo[3,4d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck - a Selective Insight. Bioorg. Med. Chem. Lett. 2002, 12, 1687-1690.
49. Stieber, F.; Mazitschek, R.; Soric, N.; Giannis, A.; Waldmann, H. Traceless Solid-Phase Synthesis of 2-Aminothiazoles: Receptor Tyrosine Kinase Inhibitors with Dual Selectivity for Tie-2 and VEGFR-2. Angew. Chem., Int. Ed. 2002, 41, 4757-4761.
50. Zhou, B.-N.; Johnson, R. K.; Mattern, M. R.; Fisher, P. W.; Kingston, D. G. I.; The First Naturally Occurring Tie 2 Inhibitor. Org. Lett. 2001, 3, 4047-4049.
51. A homology model of the IGF1R kinase domain was also created. The conclusions drawn with respect to the binding modes of the nakijiquinone analogues were essentially the same as those derived from the available crystal structures.
52. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 1999, 7, 319-330.